Ásynjur

Sigyn Therapeutics Announces Successful Completion of Animal Pilot Study

Retrieved on: 
Thursday, July 29, 2021
Health sciences, Drug discovery, Academic disciplines, Life sciences, Membrane technology, Loki, Sigyn, Ásynjur, Pilot experiment, Therapy, Clinical trial, Dialysis

The pilot study represents the first-in-mammal use of Sigyn Therapy in a clinical setting.

Key Points: 
  • The pilot study represents the first-in-mammal use of Sigyn Therapy in a clinical setting.
  • In the pilot animal study, an adult version of Sigyn Therapywas administered to two porcine (pig) subjects (each ~ 40 kilos) to evaluate the feasibility of a therapeutic protocol designed to support subsequent clinical studies.In the study, Sigyn Therapy was deployed on a standard dialysis hardware system and utilized conventional blood-tubing set configurations.
  • Craig Roberts, Chief Technical Officer at Sigyn Therapeutics, added, We are pleased with the results of our pilot study, which provides us with clinical evidence that our device can be safely used without complications or adverse events.
  • This press release contains forward-looking statements of Sigyn Therapeutics, Inc. (Sigyn) that involve substantial risks and uncertainties.

Sigyn Therapeutics Announces Force Wealth Webinar Presentation on February 16th

Retrieved on: 
Thursday, February 11, 2021
Health sciences, Immunology, Health, Loki, Sigyn, Ásynjur, Cytokine, Therapy

The webinar is an exclusive Force Family Office Event.

Key Points: 
  • The webinar is an exclusive Force Family Office Event.
  • Click on the following link to register or learn more about the event; SigynPresentation
    Sigyn Therapeutics is a development-stage therapeutic technology company headquartered in San Diego, California USA.
  • Sigyn Therapy is a novel blood purification technology designed to mitigate cytokine storm syndrome through the broad-spectrum depletion of inflammatory targets from the bloodstream.
  • This press release contains forward-looking statements of Sigyn Therapeutics, Inc. (Sigyn) that involve substantial risks and uncertainties.

Recent Milestone Achievements of Sigyn Therapeutics Discussed During CEO Interview

Retrieved on: 
Tuesday, January 19, 2021
Loki, Sigyn, Ásynjur, Ships, Shipping, Water transport

SAN DIEGO, Jan. 19, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Sigyn Therapeutics, Inc. (OTCMarkets: SIGY), disclosed today that its Chairman and CEO Jim Joyce is featured in an interview with The Wall Street Analyzer.

Key Points: 
  • SAN DIEGO, Jan. 19, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Sigyn Therapeutics, Inc. (OTCMarkets: SIGY), disclosed today that its Chairman and CEO Jim Joyce is featured in an interview with The Wall Street Analyzer.
  • During the interview, Mr. Joyce discusses recent data-driven milestones that reinforce the potential for Sigyn Therapy to overcome the limitations of previous strategies to treat sepsis and other life-threatening inflammatory conditions.
  • Sigyn Therapeutics is a medical technology company headquartered in San Diego, California USA.
  • This press release contains forward-looking statements of Sigyn Therapeutics, Inc. (Sigyn) that involve substantial risks and uncertainties.

Sight Machine Wins Investment from Sony Innovation Fund

Retrieved on: 
Wednesday, September 4, 2019
Economy, Finance, Money, Entrepreneurship, Norse mythology, Scandinavian folklore, Sif, Swedish folklore, Ásynjur, Venture capital, Innovation, Sony

SAN FRANCISCO, Sept. 4, 2019 /PRNewswire/ --Sight Machine Inc., the industry's leading digital manufacturing platform, today announced a venture capital investment from Sony Innovation Fund (SIF), Sony Corporation's venture capital arm.

Key Points: 
  • SAN FRANCISCO, Sept. 4, 2019 /PRNewswire/ --Sight Machine Inc., the industry's leading digital manufacturing platform, today announced a venture capital investment from Sony Innovation Fund (SIF), Sony Corporation's venture capital arm.
  • "Sight Machine is bringing IT and OT together in ways that have brought real operational efficiencies and manufacturing innovation to global customers in process and discrete manufacturing industries," said Gen Tsuchikawa, Head of Sony Innovation Fund.
  • SIF's investment in Sight Machine supports SIF's thesis to invest in companies that are driving innovation.
  • Established in July 2016 by Sony Corporation, Sony Innovation Fund engages with pioneering startups to help fuel the development of disruptive technologies and launch new businesses.